ProMIS Neurosciences
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1920 Yonge St Ste 200, Toronto, Ontario,...Phone Number
(416) 847-6898Website
www.promisneurosciences.comRevenue
-Stock Symbol
PMNIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada.Explore more
ProMIS Neurosciences Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ProMIS Neurosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
ProMIS Neurosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on ProMIS Neurosciences recently announced quarterly report
Click to see if ProMIS Neurosciences had a recent Job posting/layoffs
Product Launch: Get notified when ProMIS Neurosciences launches new products
Congratulate Masked Content for being promoted to Masked Content at ProMIS Neurosciences
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if ProMIS Neurosciences has recently received funding, and reach out quickly before it becomes old news!
Check out if ProMIS Neurosciences is spiking on competitors!
Funding: Get notified immidiatlly once ProMIS Neurosciences has new funding data
Recommended Actions
Find VP level buyers at ProMIS Neurosciences
Find more new buyers
Compare Similar Companies to ProMIS Neurosciences
Compare insights from companies similar to ProMIS Neurosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ProMIS Neurosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ProMIS Neurosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ProMIS Neurosciences.
ProMIS Neurosciences financials insights
Gather financial insights about ProMIS Neurosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$7M
2024
Share Placement
$3M
2025
Stock/Share Issuance
$800K
2026
Stock/Share Issuance
$175M
ProMIS Neurosciences Tech Stack
A closer look at the technologies used by ProMIS Neurosciences
See more technologies
Most Recent Scoops
Funding
Funding
Project
Research & Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Funding
Funding
Left Company
Executive Move
Executive Moves, Left Company
Earnings
Clinical Operations, Operations
ProMIS Neurosciences News & Media
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
Cambridge, Massachusetts, May 12, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update.ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that it will present two scientific posters at the Alzheimer’s & Parkinson’s Diseases Conference (AD/PD™ 2026), being held March 17–21, 2026 in Copenhagen, Denmark.ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the company will be participating in a fireside chat and investor one-on-one meetings at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12th, 2026 in New York, NY.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding ProMIS Neurosciences
Sign Up For FreeTo access detailed company insights
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada.... Read More
